The latest developments in diabetes drug discovery
Several new advances have been made in the field of drug discovery for diabetes – here, three of the most recent have been rounded up.
List view / Grid view
Articles
How labs become AI ready with advanced informatics infrastructures
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
Antibodies allow for a targeted approach to cancer therapy
Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…
The race to find a coronavirus treatment: are antibodies the answer?
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
Not everyone loves surprises: know your ADC’s critical quality attributes
The importance of product characterisation throughout the entire drug development process cannot be understated. Success, money and lives depend on it. This article delves into why you need to understand every aspect of an ADC in order to prevent unwelcome surprises down the line.
Petabytes of data – how informatics is transforming precision medicine
Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
Laboratory automation in early drug discovery
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Scientific data management: the core of quality
Gone are the days where mere data is considered king. We now understand the real value is in proper data management; but how best to harness its value? This article addresses current market options for companies wanting to extract every ounce of knowledge from raw data.
Expert view: Early product characterisation mitigates risks in biologics development
Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.
Expert view: How automation can improve cell stability and productivity in cell line development
During cell line development, key attributes such as cell productivity, stability and monoclonality are required before progressing cells for manufacturing.
Genomic assays: on the brink of revolutionising human healthcare
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
In vitro platforms for de-risking nephrotoxicity during drug development
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
Expert view: Are you ready for next generation therapeutic antibodies?
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
Expert view: Targeting the cGAS-STING pathway with a new Transcreener HTS assay
DNA in the cytoplasm is an indicator of microbial infection, serving as a danger signal and resulting in induction of an innate immune response via the cyclic GAMP synthase (cGAS)/STING (Stimulator of INterferon-sensitive Genes) pathway.
Pooling research and development resources to tackle emerging threats
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.